Assay Chart. March Thyroid. Thyroid continued on next page

Transcription

1 Chart The information in this chart is based on Version.0.CH Test Definitions. availability depends on regulatory status in each country. March 2005 Reagent Sequence Thyroid atg 00 I U/mL SP 2W (-2-4) atg dil atpo 00 I U/mL O SP 2W (-3-4) atpo dil ipth 00 D FrT4 50 I pg/ml 0. 2 ng/dl 56 4 hrs Multi-dil SP 2W (-3-4) A 450 SP W (-4) 5 7 FT3 50 I pg/ml Thyroid continued on next page A SP W (2-4) 5 Footnotes on pages 2 & 3 078D Rev. A, , ADVIA Centaur Chart (Based on Version.0.CH Test Definitions) Page

2 Reagent Sequence Thyroid continued T3 80 I T4 00 I µg/dl 4 * T3/T4/VB2 Anc 500 days T3/T4/ VB2 Anc 500 days Manual T3 dil Manual T4 dil SP W (2-4) W ( - 4) A 5 A 5 /4* TSH 00 D µlu/ml 2 -- B 225 SP W (-2-4) Multi-dil 5 TSH-3 00 D µlu/ml TSH Multi-dil SP 3W (-2A-WD-3-4) 2 TUp 50 D 4 Fertility E26 00 I pg/ml Fertility continued on next page * A 450 SP W (2-4) 5 E2-6 Antibody Reagent 00 days days * Multi-dil W (-4) 6 2 /* Footnotes on pages 2 & 3 078D Rev. A, , ADVIA Centaur Chart (Based on Version.0.CH Test Definitions) Page 2

3 Reagent Sequence Fertility continued E2-6III 00 I pg/ml 50 Anc No 6 Multi-dil / W (-4) 2 FSH 00 D mlu/ml * B Multi-dil SP 2W (-3-4) 5 / * LH 60 D mlu/ml Multi-dil SP 2W (-3-4) B 5 PRGE 50 I PRGE Releasing Agent 50 days Multi-dil SP 2W (-3-4) E 2 PRL 50 D B Multi-dil SP 2W (-2A-3D-4) 5 ThCG 50 D TSTO 50 I mlu/ml ng/dl 2 7 * B 450 SP W (-3-4) ThCG dil 5 TSTO Buffer TSTO Releasing Agent 00 7 days days * Multi-dil SP W (2-4) E 2 6/7 * Footnotes on pages 2 & 3 078D Rev. A, , ADVIA Centaur Chart (Based on Version.0.CH Test Definitions) Page 3

4 Reagent Sequence Oncology AFP 00 D * D W (-3-4) Multi-dil 2 2 / * BR 50 I U/mL BR Pre-treatment 200 days Multi-dil W (-3-4) G 2 7 CA25 00 D U/mL NO WASH /20 50 Multi-dil 2 2W (-3-4) 2 CA53 00 D U/mL (4.65 ml) 2W (W-3W-4) Anc RSW /20 20 Multi-dil 2 2W (W-3W-4) 2 CA99 50 D U/mL and (5.40 ml) 350 SP 3W (W-2W-3W- 9 4) RS /20 75 CA99 dil 2 3W (W-2W-3-4) 2 CEA 00 D Oncology continued on next page... D W (-3-4) CEA dil 2 2 Footnotes on pages 2 & 3 078D Rev. A, , ADVIA Centaur Chart (Based on Version.0.CH Test Definitions) Page 4

5 Reagent Sequence Oncology continued cpsa 00 D cpsa Pre-treatment hours Multi-dil W (-3-4) Y 2 2 H2n 50 D KM99 D Anc Multi-dil W (-3-4) 2 liq KM99 dil 2W (-2-4) PSA 00 D Anemia Q W (-3-4) Multi-dil 2 2 FER 50 D C 450 SP W (-3-4) Multi-dil 5 FolateBA 00 I DTT/ Releasing T SP W (2-3-4) Fol dil 00 Anc hours DTT/ Releasing C VB2 00 I pg/ml T3/ T4/ VB2 Anc. Reagent hours VB2 dil SP 200 LR W (-4) 5 Footnotes on pages 2 & 3 078D Rev. A, , ADVIA Centaur Chart (Based on Version.0.CH Test Definitions) Page 5

6 Reagent Sequence Cardiovascular BNP 00 D < pg/ml 4 (2.70 ml) W (W-2A-WDW SP Multi-dil 3W-4) 2 CKMB 00 D K SP 2W (-3-4) CKMB dil 2 CKMBJ 00 D K SP 2W (-3-4) CKMB dil 2 ctnl 00 D U /60 ** Multi-dil SP 2W (-3-4) 2 HCY 00 I < µmol/l HCY Releasing Agent 200 days HCY dil Anc 2W (-3-4) 88 2 liq. U /60 ** MYO 50 D Multi-dil SP 2W (-3-4) 2 Footnotes on pages 2 & 3 078D Rev. A, , ADVIA Centaur Chart (Based on Version.0.CH Test Definitions) Page 6

7 Reagent Sequence Therapeutic Drug Monitoring CARB 50 I DGTN 50 I * Z 400 SP W (-3-4) Multi-dil 5 5 Z W (-3-4) Multi-dil 5 5 /7 * DIG 50 I * B W (-2-4) Multi-dil 4 5 /3 * GENT 50 I J 400 SP W (-2-4) Multi-dil PHNB 50 I PHNB Releasing Agent 00 days Multi-dil SP 2W (-2-4) L 2 liq. PHTN 50 I N SP 2W (-2-4) Multi-dil 5 2 liq. THEO2 50 I TOBR 50 I Therapeutic Drug Monitoring continued on next page SP W (-2-4) Multi-dil 3 5 Z 400 SP W (-3-4) Multi-dil Footnotes on pages 2 & 3 078D Rev. A, , ADVIA Centaur Chart (Based on Version.0.CH Test Definitions) Page 7

8 Reagent Sequence Therapeutic Drug Monitoring continued VALP 50 I VANC 50 I Infectious Disease ahavm, 3 00 D ahavt, 4 00 I ahbcm 00 D ahbct 200 D ahbs 200 D S/CO 0 00 mlu/ml miu/ml Infectious Disease continued on next page Multi-dil SP W (3-4) 5 V SP 2W (-3-4) Multi-dil 7 2 (5.90 ml) (2.70 ml) and APW (5.85 ml) (6.55 ml) and APW (3.5 ml) ahavma 00 4 days Multi-dil / SP 50 Anc 3W (W - 2A- WDW-3W-4) RSW 3W (W - 2A- WDW-3W-4) 70 2 liq. ahavta 00 Anc No 73 Manual 00 Multi-dil 20/ SP 3W (W-2A liq. 4 days WDW-3W-4) 3W (W-2A-WDW- ahbcma 57 3W-4) RSW 00 20/ LR 3W (W-2A-WDW- 2 liq. 4 days 3W-4) 3W (W-2A-WDW- ahbcta 25 SP 78 3W-4) RSW 30 Anc / W (W-2A-WDW- 2 liq W-4) ahbs 00 SP 3W (W-2A Anc WDW-3W-4) 2 liq. Footnotes on pages 2 & 3 078D Rev. A, , ADVIA Centaur Chart (Based on Version.0.CH Test Definitions) Page 8

9 Reagent (minutes ) (hours ) Sequence Infectious Disease continued ahcv, 200 D HAVT 2, 4 00 I 0 00 mlu/ml HBcT 200 D HBs 200 D HIV, 200 D EHIV, 200 D Conf (A) N/A 4 Infectious Disease continued on next page (6.45 ml) 4 days (2.70 ml) and APW (6.55 ml) and APW 999 (3.5 ml) and APW (5.70 ml) (5.70 ml) 3W(W-2A-WDW- ahcva 00 SP 62 3W-4)RSW 50 Anc / W(W-2A-WDW- 2 liq. 3W-4) HAVTA 00 Anc No 73 Manual Multi-dil 20/ liq. 75 SP 3W (W-2A- WDW-3W-4) 4 days 3W (W-2A-WDW- HBcTA 25 SP 78 3W-4) RSW 30 Anc / W (W-2A-WDW- 2 liq. 3W-4) HBsA (LR) days / SP 25 Anc 00 SP 50 Anc 3W (W-2A-WDW- 3W-4) 3W (W - 2A- WDW-3W-4)RSW 2 liq W (W - 2A- WDW-3W-4) 2 liq. 3W (W - 2A- 00 SP 69 WDW-3W-4)RSW 50 Anc 20/ W (W - 2A- 2 liq. WDW-3W-4) A 63 (3.5 ml) /20 00 N/A Multi-dil 2 05 SP 3W (W-2A- 2 4 days 25 Anc WDW-3W-4) 2 liq. 2 Footnotes on pages 2 & 3 078D Rev. A, , ADVIA Centaur Chart (Based on Version.0.CH Test Definitions) Page 9

10 Reagent Sequence Infectious Disease continued Conf (B) RubG 00 D RubM 3 50 D ToxG 00 D ToxM 50 D Adrenal Function N/A IU/mL IU/mL B 63 (3.5 ml) N/A /20 00 Multi-dil 2 05 SP 3W (W-2A- 2 2 liq. 2 and APW 4 days 25 Anc WDW-3W-4) 200 SP RubG W (-2-3-4) and 3W (W-2W-3W- 4) RSW RubM (4.90 ml) /20 20 Multi-dil 2 2 3W (W-2A-WDW- 3-4) 3W (W-2A- WDW- (5.58 ml) 3W-4) RSW 20/20 0 Tox G 2 3W (W-2A- WDW- 3W-4) and SP 3W (W-2A- WDW- 3W-4) RS Tox M (6.30 ml) 20/ LR 3W (W-2A- WDW- 3W-4) 0.6 liq. COR 50 I µg/dl 0 E W (3-4) Multi-dil Footnotes on pages 2 & 3 078D Rev. A, , ADVIA Centaur Chart (Based on Version.0.CH Test Definitions) Page 0

11 Reagent Sequence Allergy ALSCRN 50 D 3 (4.5 ml) 2W (WDW3-3W3-4) 00 SP RSW3 R 8 hrs 7.5/ Anc 3W (W3-2A- 0.5 WDW3-3W3-4) lge 50 D lu/ml B 450 SP W (-3-4) lge dil 5 RefAllgn 0-60 sige ku/l 82 8 hrs 3 (4.5 ml) 7.5/ Vial 0.5 liq. 2W (WDW3-3W3-00 SP 4) RSW3 7.5/ Vial 3W (W3-2A-WDW3-3W3-4) Specific Allergens 0 or / Vial Other CpS 00 D W (-2-4) Multi-dil 0 IRI 00 D mu/l 2 66 IRI dil W (-2-4) Footnotes on pages 2 & 3 078D Rev. A, , ADVIA Centaur Chart (Based on Version.0.CH Test Definitions) Page

12 Footnotes: * Refers to low volume usage. Consult the ADVIA Centaur Manual. I (Inverse) and D (Direct) refer to the relationship that exists between the amount analyte present in a patient sample and the amount RLUs detected by the system. Manually dilute with diluent, if required. Refer to the assay's age insert (instructions for use) for details concerning the order reagent pickup. Currently available outside the United States only. Specific Allergen dependent ** Stored at -20 C available in Japan, contact your local technical support provider or distributor for additional information. Explanation Sequence at Block W, 2W, or 3W Manufactured for Ortho-Clinical Diagnostics, Inc. by Bayer HealthCare LLC. available in United States only. is required to form the assay and must be on-board prior to starting the run. is only for ahavt/havt levels > 00 miu/ml. See IFU for dilution recommendations. One, two, or three wash steps in the sequence 2D or 3D dispense only at Dispense Port 2 (2D) or Dispense Port 3 (3D), 2, or 3 dispense at Dispense Port, Dispense Port 2, or Dispense Port 3, following aspiration at each corresponding Aspirate position 2DW, 3DW, or WDW 4 Aspiration only at Aspirate 4 2DW3, 3DW3, or WDW3 W, 2W, or 3W W3, 2W3, or 3W3 Dispense at Dispense Port (W), Dispense Port 2 (2W), or Dispense Port 3 (3W) following aspiration at each corresponding Aspirate position Dispense 3 at Dispense Port (W3), Dispense Port 2 (2W3), or Dispense Port 3 (3W3) following aspiration at each corresponding Aspirate position A, 2A, or 3A Aspirate only at Aspirate (A), Aspirate (2A), or Aspirate (3A) WD, WDW, or WDW3 WaRS, WRS, or W3RS dispense only at Dispense Port 2 (2DW), Dispense Port 3 (3DW), or Displacement Port (WDW) 3 dispense only at Dispense Port 2 (2DW3), Dispense Port 3 (3DW3), or Displacement Port (WDW3) Displacement Port dispenses only water (WD), System (WDW), or System 3 (WDW3) Resuspend Port dispenses only water (WaRS), System (WRS), or System 3 (W3RS) Footnotes on pages 2 & 3 078D Rev. A, , ADVIA Centaur Chart (Based on Version.0.CH Test Definitions) Page 2

13 Example Sequence at Block ToxG first pass sequence, 3W (W-2A-WDW-3W-4) WRS, indicates that it has three wash steps in the sequence (3W): dispense at Dispense Port following aspiration (W) Aspirates only at Aspirate (2A) dispense at Displacement Port (WDW) dispense at Dispense Port 3 following aspiration (3W) Aspirates only at Aspirate 4 (4) dispense at Resuspend Port (WRS) Other Notes: Not all assays may be available in your area, contact your local technical support provider or distributor for availability. To identify the acceptability the calibration curve, determine the status the calibration, and if valid, then compare control values to expected values. If controls are out range, prepare fresh reagents, calibrators, and controls, form routine cleaning, and then recalibrate the tests. The information in this chart is updated to Version.0.CH Test Definitions and is correct at the time printing. However, Bayer HealthCare continues to improve products, and reserves the right to change specifications, equipment, and maintenance procedures at any time without notice. For current information, refer to the age insert. ADVIA Centaur is a trademark Bayer HealthCare LLC Bayer HealthCare LLC. All rights reserved. Bayer HealthCare LLC., Tarrytown, New York USA Footnotes on pages 2 & 3 078D Rev. A, , ADVIA Centaur Chart (Based on Version.0.CH Test Definitions) Page 3